US Stock MarketDetailed Quotes

AGX Argan

Watchlist
  • 140.300
  • +1.790+1.29%
Trading Dec 19 11:08 ET
1.90BMarket Cap29.23P/E (TTM)

Argan Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Oct 31, 2024
(Q2)Jul 31, 2024
(Q1)Apr 30, 2024
(FY)Jan 31, 2024
(Q4)Jan 31, 2024
(Q3)Oct 31, 2023
(Q2)Jul 31, 2023
(Q1)Apr 30, 2023
(FY)Jan 31, 2023
(Q4)Jan 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-44.93%31.78M
105.29%73.5M
1,517.15%17.69M
488.74%116.86M
-42.71%24.6M
455.97%57.71M
310.03%35.8M
96.86%-1.25M
-205.79%-30.06M
423.15%42.93M
Net income from continuing operations
412.63%28.01M
42.54%18.2M
273.73%7.88M
-6.76%32.36M
-21.14%12.02M
-29.57%5.46M
202.39%12.77M
-71.82%2.11M
-2.81%34.7M
4,817.96%15.24M
Operating gains losses
----
----
----
111.68%130K
----
----
----
----
-338.84%-1.11M
-101.61%-1K
Depreciation and amortization
-9.54%531K
-4.27%561K
-10.54%577K
-35.26%2.41M
-27.35%587K
-38.34%587K
-40.20%586K
-33.85%645K
-12.32%3.72M
-18.96%808K
Deferred tax
-14.72%591K
160.06%206K
78.91%263K
141.24%1.33M
127.65%836K
219.07%693K
-345.45%-343K
-67.33%147K
-1,453.85%-3.23M
-411.51%-3.02M
Other non cash items
234.20%1.29M
211.58%973K
163.35%4.15M
-317.31%-1.8M
-460.36%-1.54M
-345.27%-959K
-606.98%-872K
193.12%1.58M
-75.34%826K
-179.48%-275K
Change In working capital
-99.64%185K
133.79%52.55M
153.25%3.6M
212.98%77.97M
-60.51%11.53M
296.88%50.73M
197.98%22.48M
86.34%-6.76M
-138.99%-69.01M
216.76%29.18M
-Change in receivables
-248.61%-35.13M
-6,837.65%-27.56M
-304.21%-18.83M
52.12%-20.65M
20.94%-20.2M
36.57%-10.08M
-95.63%409K
183.49%9.22M
-302.81%-43.12M
-319.93%-25.55M
-Change in payables and accrued expense
-83.13%3.19M
83.47%33.04M
127.76%7.48M
63.25%14.83M
-71.41%4.87M
131.17%18.89M
2,112.18%18.01M
-76.90%-26.94M
258.20%9.08M
19.77%17.04M
-Change in other current assets
590.09%15.18M
-473.97%-6.24M
-8.14%-4.42M
69.99%-1M
120.70%1.97M
171.68%2.2M
-109.42%-1.09M
-78.48%-4.09M
-1,288.38%-3.35M
-312.38%-9.53M
-Change in other working capital
-57.32%16.95M
935.49%53.31M
28.76%19.38M
368.09%84.79M
-47.31%24.89M
365.02%39.71M
111.99%5.15M
171.92%15.05M
28.37%-31.63M
197.33%47.23M
Cash from discontinued investing activities
Operating cash flow
-44.93%31.78M
105.29%73.5M
1,517.15%17.69M
488.74%116.86M
-42.71%24.6M
455.97%57.71M
310.03%35.8M
96.86%-1.25M
-205.79%-30.06M
423.15%42.93M
Investing cash flow
Cash flow from continuing investing activities
-16.97%-82.28M
-111.09%-42.83M
-106.01%-1.73M
-7.11%-67.61M
-624.30%-5.72M
-401.82%-70.34M
-4,973.00%-20.29M
133.73%28.75M
-796.87%-63.12M
56.83%-790K
Net PPE purchase and sale
-129.05%-2.55M
-508.55%-2.35M
50.08%-322K
18.27%-2.76M
22.41%-613K
42.80%-1.11M
3.50%-386K
-171.01%-645K
-137.13%-3.37M
-164.21%-790K
Net business purchase and sale
--0
--0
---3.31M
---5.11M
---5.11M
--0
--0
--0
--0
----
Net investment purchase and sale
-15.17%-79.74M
-103.38%-40.49M
-93.52%1.91M
0.01%-59.74M
--0
-374.18%-69.23M
---19.91M
134.58%29.4M
---59.75M
--0
Cash from discontinued investing activities
Investing cash flow
-16.97%-82.28M
-111.09%-42.83M
-106.01%-1.73M
-7.11%-67.61M
-624.30%-5.72M
-401.82%-70.34M
-4,973.00%-20.29M
133.73%28.75M
-796.87%-63.12M
56.83%-790K
Financing cash flow
Cash flow from continuing financing activities
-24.78%-6.93M
7.24%-5.56M
21.19%-5.12M
68.54%-26.05M
11.35%-8M
58.78%-5.56M
79.72%-6M
78.86%-6.49M
-139.26%-82.8M
62.65%-9.03M
Net common stock issuance
73.45%-459K
--0
94.92%-187K
81.73%-12.46M
19.80%-4M
82.85%-1.73M
88.28%-3.06M
86.41%-3.68M
-234.95%-68.24M
75.54%-4.98M
Cash dividends paid
-30.30%-5.2M
-20.98%-4.04M
-19.90%-4.03M
-5.21%-14.68M
-18.68%-4M
-17.40%-3.99M
3.97%-3.34M
9.56%-3.36M
10.90%-13.96M
12.13%-3.37M
Proceeds from stock option exercised by employees
----
-476.92%-1.52M
-266.54%-906K
1,562.12%1.1M
----
----
--403K
724.24%544K
-95.38%66K
--0
Net other financing activities
----
----
----
----
----
----
----
----
---677K
----
Cash from discontinued financing activities
Financing cash flow
-24.78%-6.93M
7.24%-5.56M
21.19%-5.12M
68.54%-26.05M
11.35%-8M
58.78%-5.56M
79.72%-6M
78.86%-6.49M
-139.26%-82.8M
62.65%-9.03M
Net cash flow
Beginning cash position
13.62%232.69M
6.02%207.74M
13.27%197.03M
-50.37%173.95M
36.38%185.57M
42.87%204.8M
1.92%195.95M
-50.37%173.95M
-4.42%350.47M
-65.25%136.07M
Current changes in cash
-215.78%-57.44M
163.84%25.1M
-48.40%10.84M
113.18%23.2M
-67.17%10.87M
-184.83%-18.19M
120.23%9.51M
113.49%21.01M
-1,230.10%-175.99M
184.27%33.11M
Effect of exchange rate changes
109.70%101K
77.00%-152K
-113.51%-134K
78.48%-116K
-87.56%594K
-16.57%-1.04M
65.10%-661K
139.27%992K
81.84%-539K
364.63%4.77M
End cash Position
-5.51%175.35M
13.62%232.69M
6.02%207.74M
13.27%197.03M
13.27%197.03M
36.38%185.57M
42.87%204.8M
1.92%195.95M
-50.37%173.95M
-50.37%173.95M
Free cash flow
-48.35%29.23M
100.89%71.15M
1,017.27%17.36M
441.29%114.1M
-43.09%23.98M
411.73%56.6M
303.00%35.42M
95.26%-1.89M
-223.86%-33.43M
410.22%42.14M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Oct 31, 2024(Q2)Jul 31, 2024(Q1)Apr 30, 2024(FY)Jan 31, 2024(Q4)Jan 31, 2024(Q3)Oct 31, 2023(Q2)Jul 31, 2023(Q1)Apr 30, 2023(FY)Jan 31, 2023(Q4)Jan 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -44.93%31.78M105.29%73.5M1,517.15%17.69M488.74%116.86M-42.71%24.6M455.97%57.71M310.03%35.8M96.86%-1.25M-205.79%-30.06M423.15%42.93M
Net income from continuing operations 412.63%28.01M42.54%18.2M273.73%7.88M-6.76%32.36M-21.14%12.02M-29.57%5.46M202.39%12.77M-71.82%2.11M-2.81%34.7M4,817.96%15.24M
Operating gains losses ------------111.68%130K-----------------338.84%-1.11M-101.61%-1K
Depreciation and amortization -9.54%531K-4.27%561K-10.54%577K-35.26%2.41M-27.35%587K-38.34%587K-40.20%586K-33.85%645K-12.32%3.72M-18.96%808K
Deferred tax -14.72%591K160.06%206K78.91%263K141.24%1.33M127.65%836K219.07%693K-345.45%-343K-67.33%147K-1,453.85%-3.23M-411.51%-3.02M
Other non cash items 234.20%1.29M211.58%973K163.35%4.15M-317.31%-1.8M-460.36%-1.54M-345.27%-959K-606.98%-872K193.12%1.58M-75.34%826K-179.48%-275K
Change In working capital -99.64%185K133.79%52.55M153.25%3.6M212.98%77.97M-60.51%11.53M296.88%50.73M197.98%22.48M86.34%-6.76M-138.99%-69.01M216.76%29.18M
-Change in receivables -248.61%-35.13M-6,837.65%-27.56M-304.21%-18.83M52.12%-20.65M20.94%-20.2M36.57%-10.08M-95.63%409K183.49%9.22M-302.81%-43.12M-319.93%-25.55M
-Change in payables and accrued expense -83.13%3.19M83.47%33.04M127.76%7.48M63.25%14.83M-71.41%4.87M131.17%18.89M2,112.18%18.01M-76.90%-26.94M258.20%9.08M19.77%17.04M
-Change in other current assets 590.09%15.18M-473.97%-6.24M-8.14%-4.42M69.99%-1M120.70%1.97M171.68%2.2M-109.42%-1.09M-78.48%-4.09M-1,288.38%-3.35M-312.38%-9.53M
-Change in other working capital -57.32%16.95M935.49%53.31M28.76%19.38M368.09%84.79M-47.31%24.89M365.02%39.71M111.99%5.15M171.92%15.05M28.37%-31.63M197.33%47.23M
Cash from discontinued investing activities
Operating cash flow -44.93%31.78M105.29%73.5M1,517.15%17.69M488.74%116.86M-42.71%24.6M455.97%57.71M310.03%35.8M96.86%-1.25M-205.79%-30.06M423.15%42.93M
Investing cash flow
Cash flow from continuing investing activities -16.97%-82.28M-111.09%-42.83M-106.01%-1.73M-7.11%-67.61M-624.30%-5.72M-401.82%-70.34M-4,973.00%-20.29M133.73%28.75M-796.87%-63.12M56.83%-790K
Net PPE purchase and sale -129.05%-2.55M-508.55%-2.35M50.08%-322K18.27%-2.76M22.41%-613K42.80%-1.11M3.50%-386K-171.01%-645K-137.13%-3.37M-164.21%-790K
Net business purchase and sale --0--0---3.31M---5.11M---5.11M--0--0--0--0----
Net investment purchase and sale -15.17%-79.74M-103.38%-40.49M-93.52%1.91M0.01%-59.74M--0-374.18%-69.23M---19.91M134.58%29.4M---59.75M--0
Cash from discontinued investing activities
Investing cash flow -16.97%-82.28M-111.09%-42.83M-106.01%-1.73M-7.11%-67.61M-624.30%-5.72M-401.82%-70.34M-4,973.00%-20.29M133.73%28.75M-796.87%-63.12M56.83%-790K
Financing cash flow
Cash flow from continuing financing activities -24.78%-6.93M7.24%-5.56M21.19%-5.12M68.54%-26.05M11.35%-8M58.78%-5.56M79.72%-6M78.86%-6.49M-139.26%-82.8M62.65%-9.03M
Net common stock issuance 73.45%-459K--094.92%-187K81.73%-12.46M19.80%-4M82.85%-1.73M88.28%-3.06M86.41%-3.68M-234.95%-68.24M75.54%-4.98M
Cash dividends paid -30.30%-5.2M-20.98%-4.04M-19.90%-4.03M-5.21%-14.68M-18.68%-4M-17.40%-3.99M3.97%-3.34M9.56%-3.36M10.90%-13.96M12.13%-3.37M
Proceeds from stock option exercised by employees -----476.92%-1.52M-266.54%-906K1,562.12%1.1M----------403K724.24%544K-95.38%66K--0
Net other financing activities -----------------------------------677K----
Cash from discontinued financing activities
Financing cash flow -24.78%-6.93M7.24%-5.56M21.19%-5.12M68.54%-26.05M11.35%-8M58.78%-5.56M79.72%-6M78.86%-6.49M-139.26%-82.8M62.65%-9.03M
Net cash flow
Beginning cash position 13.62%232.69M6.02%207.74M13.27%197.03M-50.37%173.95M36.38%185.57M42.87%204.8M1.92%195.95M-50.37%173.95M-4.42%350.47M-65.25%136.07M
Current changes in cash -215.78%-57.44M163.84%25.1M-48.40%10.84M113.18%23.2M-67.17%10.87M-184.83%-18.19M120.23%9.51M113.49%21.01M-1,230.10%-175.99M184.27%33.11M
Effect of exchange rate changes 109.70%101K77.00%-152K-113.51%-134K78.48%-116K-87.56%594K-16.57%-1.04M65.10%-661K139.27%992K81.84%-539K364.63%4.77M
End cash Position -5.51%175.35M13.62%232.69M6.02%207.74M13.27%197.03M13.27%197.03M36.38%185.57M42.87%204.8M1.92%195.95M-50.37%173.95M-50.37%173.95M
Free cash flow -48.35%29.23M100.89%71.15M1,017.27%17.36M441.29%114.1M-43.09%23.98M411.73%56.6M303.00%35.42M95.26%-1.89M-223.86%-33.43M410.22%42.14M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
+3.16%
Halozyme Therapeutics
HALO
+1.86%
Teradata Corp
TDC
+1.30%
Hutchmed (China)
HCM
+0.83%
Collegium Pharmaceutical
COLL
+0.80%

Unlock the Full List